

TOPCON CORPORATION

FY2025 Q1 Financial Results

July 28, 2025

Highlights

● FY25 Q1 Financial Results

Consolidated

Net Sales **¥48.5B**
YoY -6%

Operating Income **-¥0.5B**
YoY -

Positioning Business

YoY
Net Sales 
Operating Income 

- ✓ Sales decreased due to sluggish demand in IT Construction and IT Agriculture, more than offsetting an increase that reflected the effects of new products for surveying instruments and GNSS.
- ✓ Profits declined due to a decrease in sales, despite of fixed cost reductions.

Eye Care Business

YoY
Net Sales 
Operating Income 

- ✓ Sales were strong mainly in North America.
- ✓ Profits increased despite a rise in expenses related to growth investment.

FY25 Q1 Financial Results

Consolidated Financial Results

(Unit: billion yen)		FY2024 Q1 Actual	FY2025 Q1 Actual	YoY	%
Net Sales		51.4	48.5	-2.9	-6%
Gross Profit		27.6	25.8	-1.8	-7%
Gross Profit Ratio		53.6%	53.1%	-0.5pt	
SGA		26.9	26.3	-0.6	-2%
Operating Income		0.7	-0.5	-1.2	-
Operating Income Ratio		1.3%	-1.0%	-2.4pt	
Ordinary Income		-0.4	-0.8	-0.4	-
Extraordinary Losses		-	-1.5	-1.5	-
Net Income		-1.0	-2.1	-1.1	-
Exchange rate					
(Average)	USD	¥156.53	¥145.19	-¥11.34	
	EUR	¥168.37	¥164.37	-¥4.00	

YoY comparisons
 excluding FX effects
 -¥0.3B (-1%)

Overview | Positioning Business

- Sales decreased due to sluggish demand in IT Construction and IT Agriculture, more than offsetting an increase that reflected the effects of new products for surveying instruments and GNSS.
- Profits declined due to a decrease in sales, despite of fixed cost reductions.

(Unit: billion yen)		FY2024 Q1 Actual	FY2025 Q1 Actual	YoY	%
Net Sales		33.8	30.5	-3.3	-10%
Operating Income		1.9	1.5	-0.4	-19%
Operating Income Ratio		5.6%	5.0%	-0.6pt	
Exchange rate (Average)	USD	¥156.53	¥145.19	-¥11.34	
	EUR	¥168.37	¥164.37	-¥4.00	

YoY comparisons excluding
FX effects -¥1.6B (-5%)

Overview | Eye Care Business


- Sales were strong mainly in North America.
- Profits increased despite a rise in expenses related to growth investment.

(Unit: billion yen)		FY2024 Q1 Actual	FY2025 Q1 Actual	YoY	%
Net Sales		17.6	17.9	+0.3	+2%
Operating Income		0.0	0.1	+0.1	+576%
Operating Income Ratio		0.1%	0.4%	+0.3pt	
Exchange rate (Average)	USD	¥156.53	¥145.19	-¥11.34	
	EUR	¥168.37	¥164.37	-¥4.00	

YoY comparisons
excluding FX effects
+¥1.2B (+7%)

Consolidated | Operating Income YoY Breakdown

(Unit: billion yen)



*1 ECB: Eye Care Business

Positioning Business

- We improved speed to market of new products after we bolstered our development process and structure as outlined in the mid-term plan.
- Our presence and leadership in the industry were demonstrated in the industry-leading exhibitions.

New Products



Layout Navigator
LN-160

Dec, 2024



Motor Drive Total Station
GT/iX-1500/700

Jan, 2025



GNSS Receiver
HiPer XR/GRX5

Feb 2025

Further acceleration
toward the next release



MC-Max Excavator
GX-90

Mar, 2025



3D Measurement Workflow
Collage Site ver1.7.4/1.8

Apr, 2025



3D Laser Scanner
CR-P1

Apr, 2025

Exhibitions

BAUMA 2025 (Munich, Germany)

We showcased the value of our solutions by telling stories.




World's largest construction machinery exhibition

- Number of visitors: **600,000** (Last time: 495,000)
- From April 7, 2025 to April 13, 2025

CSPI-EXPO 2025 (Makuhari, Japan)

We had a preview exhibition of our new products, thereby strengthening relationships with domestic customers.



Japan's largest construction and surveying exhibition


- Number of visitors: **57,000** over four days (Last time: 47,000)
- From June 18, 2025 to June 21, 2025

Eye Care Business

- We accelerated "Healthcare from the eye" through aggressive investment.
- We completed the acquisition of RetInSight GmbH, an AI provider.

Business Model

"Healthcare from the eye"



Acquisition

Acquisition of RetInSight GmbH completed (2025 May)

(News Release)



- An AI provider based in Austria
- GmbH mainly develops AI for analyzing OCT data.
- We strengthened the Screening Business using AI.


Appendix

- Financial Results
- Sales Ratio by Region
- Capital Expenditure, Depreciation and R&D


Appendix

Financial Results | Consolidated

Quarterly





Annual




Appendix

Financial Results | Positioning Business






Appendix

Financial Results | Eye Care Business



Appendix


Sales Ratio by Region



Capital Expenditure, Depreciation and R&D


Capital Expenditure

(Unit: billion yen)




Depreciation

(Unit: billion yen)



R&D

(Unit: billion yen)



Cautionary Note regarding Forward-Looking Statements

The information contained in this document has been prepared based on currently available data and includes forward-looking statements, expectations, plans, and descriptions of the business environment.

Please be advised that actual results may differ from those described herein due to changes in economic conditions, market trends, and other factors.

Inquiries

Corporate Planning & Digital Business Operation Div.
Corporate Communication Dept.
TOPCON CORPORATION
TEL : +81-3-3558-2532
E-mail: investor_info@topcon.co.jp
URL: <https://global.topcon.com/invest/>